APREHealthcare · BiotechnologyThe 4 Wall Street analysts covering Aprea Therapeutics, Inc. hold a median 12-month price target of $3.5 — +622.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 31 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Aprea Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Value (14): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on APRE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +622.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Oct 2026 | Ladenburg Thalmann | Initiates | Buy | $2.00 |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | $6.00 → $3.00 |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 14 May 2026 | Wedbush | Maintains | Outperform | $7.00 → $6.00 |
| 14 May 2026 | Wedbush | Maintains | Outperform | — |
| 7 May 2026 | Oppenheimer | Initiates | Outperform | $5.00 |
| 7 May 2026 | Oppenheimer | Initiates | Outperform | — |
| 31 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 10 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 29 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2024 | Wedbush | Reiterates | Outperform | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
APRE appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Aprea Therapeutics, Inc. returned −66.6% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 1% of US stocks
Cheaper than 89% of US stocks
Cheaper than 56% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 22% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aprea Therapeutics, Inc. has a market value of $6.1M and an enterprise value of −$34.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$12.3M.
Diluted earnings per share, trailing twelve months: $−1.08.
Free cash flow in the twelve months to 30 June 2026: −$12.2M.
Trailing P/E: 0.5×; forward P/E: −1.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Aprea Therapeutics, Inc. employs 8 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aprea Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aprea Therapeutics announced it will host a virtual panel discussion titled “The State of WEE1 Inhibition in Precision Oncology” on October 20, 2026, at 11 a.m. ET.
Why it matters — The event highlights Aprea’s focus on WEE1 inhibition in precision oncology, a topic relevant to the company’s targeted-therapy work.
Aprea Therapeutics announced it will participate in the 2026 Maxim Growth Summit on October 14 and the Regional Biotechnology Conference on October 15. The company is set to present at these two upcoming industry events.
Why it matters — APRE watchers would care because these conference presentations give the company a platform to share updates and increase its visibility within the biotech and investment community.
Aprea Therapeutics announced that updated interim results from the ongoing Phase 1 ACESOT-1051 study of its WEE1 inhibitor APR-1051 in patients with advanced solid tumors were accepted for oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026), scheduled for November 18-20, 2026, in Barcelona, Spain.
Why it matters — APRE watchers would care because an oral presentation of interim Phase 1 data for APR-1051 at a major oncology symposium provides an opportunity to track progress and clinical findings for one of the company's key development programs.
Aprea Therapeutics announced that its President and CEO, Oren Gilad, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference, held in person and virtually from September 14-16, 2026. The announcement was made on September 10, 2026, from the company's headquarters in Doylestown, Pennsylvania.
Why it matters — APRE watchers may be interested because the company's leadership will have a platform to present its clinical-stage oncology pipeline to the investment community at a major industry conference.
Aprea Therapeutics announced an expansion of its intellectual property portfolio for its precision oncology programs, now holding 28 issued and 30 pending patents globally. The company stated the expansion strengthens its global intellectual property position.
Why it matters — An expanded patent portfolio could help protect Aprea's proprietary oncology programs and strengthen its competitive position in the precision oncology space.
The 4 Wall Street analysts covering Aprea Therapeutics, Inc. have a median 12-month price target of $3.5, with estimates ranging from $1.2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Aprea Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aprea Therapeutics, Inc. 44 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Aprea Therapeutics, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +622.2% from the last close, and Ticker Nerd's factor model ranks Aprea Therapeutics, Inc. 44 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aprea Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.2 to $5 over the next 12 months.
Aprea Therapeutics, Inc. returned -66.6% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers.
The most recent item we track (GlobeNewsWire, 16 Oct 2026): "Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology". Aprea Therapeutics announced it will host a virtual panel discussion titled “The State of WEE1 Inhibition in Precision Oncology” on October 20, 2026, at 11 a.m. ET.
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers. The company develops targeted cancer therapies designed to exploit DNA damage response and synthetic lethality pathways, aiming to address vulnerabilities in tumor cells while limiting impact on healthy tissue. Its current pipeline centers on investigational small-molecule programs, including APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both being evaluated in clinical development for solid tumor indications. Aprea Therapeutics concentrates on oncology research and drug development for cancers with high unmet medical need, supporting its role in the broader market for targeted and precision medicine therapeutics. The company is headquartered in Doylestown, Pennsylvania.
CEO Dr. Oren Gilad Ph.D. · 8 employees · United States · https://aprea.com
